NovaBay Pharmaceuticals, Inc. (NBY)
| Market Cap | 10.41M |
| Revenue (ttm) | 9.24M |
| Net Income (ttm) | -5.15M |
| Shares Out | 51.42M |
| EPS (ttm) | -0.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 632,333 |
| Open | 0.209 |
| Previous Close | 0.194 |
| Day's Range | 0.190 - 0.217 |
| 52-Week Range | 0.170 - 0.880 |
| Beta | 3.40 |
| Analysts | Buy |
| Price Target | 3.29 (+1,524.7%) |
| Earnings Date | May 12, 2022 |
About NBY
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne unde...
Financial Performance
In 2021, NBY's revenue was $8.42 million, a decrease of -15.23% compared to the previous year's $9.93 million. Losses were -$5.82 million, -47.24% less than in 2020.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NBY stock is "Buy." The 12-month stock price forecast is 3.29, which is an increase of 1,524.69% from the latest price.
News
NovaBay Pharmaceuticals Reports First Quarter 2022 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three months ended March 31, 2022 and provides a business update. Financial res...
NovaBay Pharmaceuticals Expands Top-Selling DERMAdoctor Kakadu C and Calm Cool + Corrected Collections with New Anti-...
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skin...
NovaBay Pharmaceuticals to Hold First Quarter 2022 Conference Call on May 12
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2022 after market close on T...
NovaBay Pharmaceuticals CEO Issues Letter to Stockholders
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that Chief Executive Officer Justin Hall has issued the following Letter to Stockholders: To My Fellow ...
NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin Returns to QVC® to Discuss DERMAdoctor's Eczema Treatment
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, ...
NovaBay Pharmaceuticals Introduces Hydrating Cleansing Oil to its DERMAdoctor Calm Cool + Corrected Product Line
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skin...
NovaBay Pharmaceuticals Reports 2021 Fourth Quarter and Full Year Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2021 and provides a business update. Fin...
NovaBay Pharmaceuticals to Hold 2021 Fourth Quarter and Full Year Conference Call on March 29
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2021 after market ...
DERMAdoctor Launches New HA Serum to Expand Calm Cool + Corrected Product Line
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skin...
NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Present DERMAdoctor Eczema Treatment as QVC® On-Air...
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, ...
NovaBay Pharmaceuticals Engages Leading Chinese Marketing Firm to Drive Consumer Sales of DERMAdoctor Skincare Produc...
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, ...
NovaBay Pharmaceuticals Announces Changes to Its Board of Directors
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focused on developing and commercializing high-quality, scientifically formulated produ...
NovaBay Pharmaceuticals to Donate 2.5 Million KN95 Masks
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #KN95_masks--NovaBay Pharmaceuticals donates 2.5 million KN95 protective masks.
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”), a pharmaceutical company focused on developing and commercializing high-quality, sc...
NovaBay Pharmaceuticals Expands Its Eyecare Product Portfolio With the Launch of Lubricating Eye Drops for the Immedi...
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #Avenova--NovaBay Pharmaceuticals launches Avenova Lubricating Eye Drops for the immediate relief of dry eye symptoms.
NovaBay Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focused on developing and commercializing scientifically formulated and clinically prov...
NovaBay Pharmaceuticals Holds Special Meeting of Stockholders
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #Avenova--NovaBay Pharmaceuticals adjourns it Special Meeting of Stockholders until January 14, 2022
DERMAdoctor's Calm Cool + Corrected Eczema Balm Receives National Eczema Association Seal of Acceptance
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #DERMAdoctor--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focused on developing and commercializing high-quality, scientifi...
3 Hot Penny Stocks To Buy In December According To Insiders
Does Insider Buying Mean A Bullish Outlook For These Penny Stocks? The post 3 Hot Penny Stocks To Buy In December According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information...
NovaBay Pharmaceuticals Reports Third Quarter 2021 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2021 and provides a business update. ...
NovaBay Pharmaceuticals Closes DERMAdoctor Acquisition
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #DERMAdoctor--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the closing of the previously announced acquisition of DERMAdoctor, LLC. The Comp...
NovaBay Pharmaceuticals Closes $15.0 Million Private Placement
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #DERMAdoctor--NovaBay completes $15 million financing and expects to complete acquisition of DERMAdoctor, LLC on November 5, 2021.
NovaBay Pharmaceuticals Announces Pricing of $15.0 Million Private Placement
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #Avenova--NovaBay Pharmaceuticals announces pricing of $15 million private placement to fund acquisition of DERMAdoctor, LLC.
NovaBay Pharmaceuticals to Hold Conference Call and Webcast With Slide Presentation Today to Discuss Acquisition of D...
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that management will discuss its acquisition of DERMAdoctor on an investment community conference call ...